66248-1-Ig

antibody from Proteintech Group

Targeting: CD274 B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1

Provider product page for 66248-1-Ig

Western blot

ELISA

Immunocytochemistry

Immunohistochemistry

Flow cytometry

Antibody data

Antibody Data
Antigen structure
References [90]
Comments [0]
Validations [0]

Submit

Product number: 66248-1-Ig - Provider product page
Provider: Proteintech Group
Proper citation: Proteintech Cat#66248-1-Ig, RRID:AB_2756526
Product name: PD-L1/CD274 antibody
Antibody type: Monoclonal
Description: KD/KO validated PD-L1/CD274 antibody (Cat. #66248-1-Ig) is a mouse monoclonal antibody that shows reactivity with human, mouse, pig, rat and has been validated for the following applications: FC, IF, IHC, WB, ELISA.
Reactivity: Human, Mouse, Rat, Porcine
Host: Mouse
Conjugate: Unconjugated
Isotype: IgG
Antibody clone number: 2B11D11
Vial size: 20ul, 150ul

CD274 protein structure - 66248-1-Ig shown in red.

Submitted references The immunomodulatory effect of microglia on ECM neuroinflammation via the PD-1/PD-L1 pathway.

Shen Y, Li Y, Zhu Q, Wang J, Huang Y, Liang J, Wu X, Zhao Y
CNS neuroscience & therapeutics 2022 Jan;28(1):46-63

A miR-129-5P/ARID3A Negative Feedback Loop Modulates Diffuse Large B Cell Lymphoma Progression and Immune Evasion Through Regulating the PD-1/PD-L1 Checkpoint.

Zheng W, Lai G, Lin Q, Issah MA, Fu H, Shen J
Frontiers in cell and developmental biology 2021;9:735855

ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.

Chen X, Gao A, Zhang F, Yang Z, Wang S, Fang Y, Li J, Wang J, Shi W, Wang L, Zheng Y, Sun Y
Theranostics 2021;11(7):3392-3416

The Landscape of Immune Cells Indicates Prognosis and Applicability of Checkpoint Therapy in Hepatocellular Carcinoma.

Huang J, Zhang L, Chen J, Wan D, Zhou L, Zheng S, Qiao Y
Frontiers in oncology 2021;11:744951

CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways.

Chen X, He H, Xiao Y, Hasim A, Yuan J, Ye M, Li X, Hao Y, Guo X
Frontiers in oncology 2021;11:629350

Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.

Li E, Huang X, Zhang G, Liang T
Journal of experimental & clinical cancer research : CR 2021 Sep 3;40(1):279

PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.

Paolino G, Pantanowitz L, Barresi V, Pagni F, Munari E, Moretta L, Brunelli M, Bariani E, Vigliar E, Pisapia P, Malapelle U, Troncone G, Girolami I, Eccher A
Pathology, research and practice 2021 Oct;226:153605

Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.

Yin H, Pu N, Chen Q, Zhang J, Zhao G, Xu X, Wang D, Kuang T, Jin D, Lou W, Wu W
Cell death & disease 2021 Oct 30;12(11):1033

The PD-1/PD-L1 pathway in murine hair cycle transition: a potential anagen phase regulator.

Zhou L, Wen L, Sheng Y, Lu J, Hu R, Wang X, Lu Z, Yang Q
Archives of dermatological research 2021 Nov;313(9):751-758

Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.

Tseng YJ, Lee CH, Chen WY, Yang JL, Tzeng HT
The Journal of investigative dermatology 2021 Nov;141(11):2690-2698.e6

Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.

Shen N, Yang C, Zhang X, Tang Z, Chen X
Acta biomaterialia 2021 Nov;135:543-555

Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.

Lehmer L, Choi F, Kraus C, Shiu J, de Feraudy S, Elsensohn A
The American Journal of dermatopathology 2021 May 1;43(5):321-330

STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer.

Cavalcante RS, Ishikawa U, Silva ES, Silva-Júnior AA, Araújo AA, Cruz LJ, Chan AB, de Araújo Júnior RF
British journal of pharmacology 2021 Jun;178(11):2284-2304

Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis.

Meng X, Wang J, Zhou J, Tian Q, Qie B, Zhou G, Duan W, Zhu Y
Acta biomaterialia 2021 Jun;127:266-275

WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.

Wu M, Xia X, Hu J, Fowlkes NW, Li S
Nature communications 2021 Jun 9;12(1):3500

Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.

Liu W, Wang Y, Xie Y, Dai T, Fan M, Li C, Zou Y
Cell death discovery 2021 Jun 5;7(1):136

Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.

Yuan J, Li J, Shang M, Fu Y, Wang T
Biochemical and biophysical research communications 2021 Jul 5;561:187-194

NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.

Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, Zhang G, Guo C, Zhang X, Chen W, Yadav DK, Bai X, Liang T
Nature communications 2021 Jul 27;12(1):4536

Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.

Deng M, Li SH, Fu X, Yan XP, Chen J, Qiu YD, Guo RP
Cancer cell international 2021 Jul 12;21(1):371

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.

Tian Y, Sun X, Cheng G, Ji E, Yang S, Feng J, Zheng L
Annals of translational medicine 2021 Jan;9(2):131

Nutritional supplements in combination with chemotherapy or targeted therapy reduces tumor progression in mice bearing triple-negative breast cancer.

Guo CH, Hsia S, Chung CH, Lin YC, Shih MY, Chen PC, Peng CL, Henning SM, Hsu GW, Li Z
The Journal of nutritional biochemistry 2021 Jan;87:108504

NAD⁺ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion.

Lv H, Lv G, Chen C, Zong Q, Jiang G, Ye D, Cui X, He Y, Xiang W, Han Q, Tang L, Yang W, Wang H
Cell metabolism 2021 Jan 5;33(1):110-127.e5

NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.

Lu F, Zhao Y, Pang Y, Ji M, Sun Y, Wang H, Zou J, Wang Y, Li G, Sun T, Li J, Ma D, Ye J, Ji C
Cancer letters 2021 Jan 28;497:178-189

Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.

Imamura R, Kitagawa S, Kubo T, Irie A, Kariu T, Yoneda M, Kamba T, Imamura T
The Prostate 2021 Feb;81(3):147-156

Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy.

Liu J, Liu Q, Zhang X, Cui M, Li T, Zhang Y, Liao Q
Cancer cell international 2021 Feb 26;21(1):137

Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.

Gong C, Yu X, Zhang W, Han L, Wang R, Wang Y, Gao S, Yuan Y
Journal of nanobiotechnology 2021 Feb 25;19(1):58

The impact of tobacco exposure on tumor microenvironment and prognosis in lung adenocarcinoma by integrative analysis of multi-omics data.

Lu X, Ma L, Yin X, Ji H, Qian Y, Zhong S, Yan A, Zhang Y
International immunopharmacology 2021 Dec;101(Pt B):108253

Cascade-Responsive Hierarchical Nanosystems for Multisite Specific Drug Exposure and Boosted Chemoimmunotherapy.

Zhang J, Zhang Y, Zhao B, Lv M, Chen E, Zhao C, Jiang L, Qian H, Huang D, Zhong Y, Chen W
ACS applied materials & interfaces 2021 Dec 15;13(49):58319-58328

OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.

Pang X, Wang SS, Zhang M, Jiang J, Fan HY, Wu JS, Wang HF, Liang XH, Tang YL
Cancer immunology, immunotherapy : CII 2021 Apr;70(4):1015-1029

ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.

Wu Y, Zhang C, Liu X, He Z, Shan B, Zeng Q, Zhao Q, Zhu H, Liao H, Cen X, Xu X, Zhang M, Hou T, Wang Z, Yan H, Yang S, Sun Y, Chen Y, Wu R, Xie T, Chen W, Najafov A, Ying S, Xia H
Nature communications 2021 Apr 20;12(1):2346

Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1.

Yang Y, Wang C, Dai C, Liu X, Li W, Huang M, Zhao X, Ji D, Li J, Guo W
Acta biochimica et biophysica Sinica 2021 Apr 15;53(5):547-557

PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.

Qu S, Jiao Z, Lu G, Yao B, Wang T, Rong W, Xu J, Fan T, Sun X, Yang R, Wang J, Yao Y, Xu G, Yan X, Wang T, Liang H, Zen K
Genome biology 2021 Apr 13;22(1):104

p.P476S mutation of RBPJL inhibits the efficacy of anti-PD-1 therapy in oesophageal squamous cell carcinoma by blunting T-cell responses.

Miao L, Wei XL, Zhao Q, Qi J, Ren C, Wu QN, Wei DL, Liu J, Wang FH, Xu RH
Clinical & translational immunology 2020;9(9):e1172

Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).

Wen B, Zhao L, Wang Y, Qiu C, Xu Z, Huang K, Zhu H, Li Z, Li H
Preparative biochemistry & biotechnology 2020;50(3):252-259

BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.

Li X, Xu Z, Cui G, Yu L, Zhang X
OncoTargets and therapy 2020;13:215-224

Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer.

Shen LF, Zhou SH, Guo Y
OncoTargets and therapy 2020;13:11221-11235

LncRNA EMX2OS Induces Proliferation, Invasion and Sphere Formation of Ovarian Cancer Cells via Regulating the miR-654-3p/AKT3/PD-L1 Axis.

Duan M, Fang M, Wang C, Wang H, Li M
Cancer management and research 2020;12:2141-2154

Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma.

Zhu G, Li X, Li J, Zhou W, Chen Z, Fan Y, Jiang Y, Zhao Y, Sun G, Mao W
Journal of Cancer 2020;11(22):6516-6529

The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.

Chou CW, Yang RY, Chan LC, Li CF, Sun L, Lee HH, Lee PC, Sher YP, Ying H, Hung MC
American journal of cancer research 2020;10(8):2621-2634

Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.

Cai H, Zhang H, Jiang Y
Frontiers in oncology 2020;10:1079

PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR.

Lv J, Guo T, Qu X, Che X, Li C, Wang S, Gong J, Wu P, Liu Y, Liu Y, Xu L
Frontiers in oncology 2020;10:1067

Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.

Yan Y, Zheng L, Du Q, Yan B, Geller DA
Cancer immunology, immunotherapy : CII 2020 Sep;69(9):1891-1903

Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.

Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y, Ma F, Gao Q, Chang R, Lee HH, Zhao S, Su J, Li H, Peng J, Chen H, Yin M, Peng C, Yang N, Wang J, Liu J, Liu H, Han L, Chen X
Genome medicine 2020 Sep 28;12(1):83

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.

Qin W, Zou J, Huang Y, Liu C, Kang Y, Han H, Tang Y, Li L, Liu B, Zhao W, Yuan X
Oncoimmunology 2020 Sep 22;9(1):1824631

Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1.

Ullah M, Aoudjeghout W, Pimpie C, Pocard M, Mirshahi M
Cancers 2020 Sep 18;12(9)

α-Cyperone inhibits the proliferation of human cervical cancer HeLa cells via ROS-mediated PI3K/Akt/mTOR signaling pathway.

Pei XD, Yao HL, Shen LQ, Yang Y, Lu L, Xiao JS, Wang XY, He ZL, Jiang LH
European journal of pharmacology 2020 Sep 15;883:173355

Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Acheampong E, Abed A, Morici M, Bowyer S, Amanuel B, Lin W, Millward M, Gray ES
Cells 2020 Oct 31;9(11)

Calcium Channel Blocker Nifedipine Suppresses Colorectal Cancer Progression and Immune Escape by Preventing NFAT2 Nuclear Translocation.

Wu L, Lin W, Liao Q, Wang H, Lin C, Tang L, Lian W, Chen Z, Li K, Xu L, Zhou R, Ding Y, Zhao L
Cell reports 2020 Oct 27;33(4):108327

Synergistic anti-liver cancer effects of curcumin and total ginsenosides.

Deng Z, Xu XY, Yunita F, Zhou Q, Wu YR, Hu YX, Wang ZQ, Tian XF
World journal of gastrointestinal oncology 2020 Oct 15;12(10):1091-1103

Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics.

Wang L, Muneer A, Xie L, Zhang F, Wu B, Mei L, Lenarcic EM, Feng EH, Song J, Xiong Y, Yu X, Wang C, Gheorghe C, Torralba K, Cook JG, Wan YY, Moorman NJ, Song H, Jin J, Chen X
bioRxiv : the preprint server for biology 2020 Nov 16;

Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.

Qin T, Xia J, Liu S, Wang J, Liu H, Zhang Y, Jia Y, Li K
Thoracic cancer 2020 May;11(5):1139-1148

ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.

Liu Z, Zhao K, Wei S, Liu C, Zhou J, Gou Q, Wu X, Yang Z, Yang Y, Peng Y, Cheng Q, Liu L
Oncoimmunology 2020 May 6;9(1):1758003

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.

Liu S, Qin T, Liu Z, Wang J, Jia Y, Feng Y, Gao Y, Li K
Cell death & disease 2020 May 4;11(5):309

NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma.

Zheng S, Liu Q, Liu T, Yang L, Zhang Q, Shen T, Zhang X, Han X, Lu X
Biochemical and biophysical research communications 2020 May 21;526(1):29-34

Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.

Tay WT, Fang YH, Beh ST, Liu YW, Hsu LW, Yen CJ, Liu PY
International journal of molecular sciences 2020 Mar 31;21(7)

ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.

Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L, Xie Z, Weng L, Guo J, Li H, Ma F, Chen X, Zhao S, Su J, Yang N, Fang F, Xie Y, Tao J, Zhang J, Chen M, Peng C, Sun L, Zhang X, Liu J, Han L, Xu X, Hung MC, Chen X
Cancer cell 2020 Mar 16;37(3):324-339.e8

Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.

Yang K, Zhou J, Chen Y, Chen Y, Chen L, Zhang P, Ma L, Jiang Z, Bian J, Yin W
International immunopharmacology 2020 Jul;84:106507

Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics.

Li Q, Chen Q, Klauser PC, Li M, Zheng F, Wang N, Li X, Zhang Q, Fu X, Wang Q, Xu Y, Wang L
Cell 2020 Jul 9;182(1):85-97.e16

Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-κB pathway in lung adenocarcinoma.

Hu M, Yang J, Qu L, Deng X, Duan Z, Fu R, Liang L, Fan D
Food & function 2020 Jan 29;11(1):456-471

The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.

Komura N, Mabuchi S, Shimura K, Yokoi E, Kozasa K, Kuroda H, Takahashi R, Sasano T, Kawano M, Matsumoto Y, Kodama M, Hashimoto K, Sawada K, Kimura T
Cancer immunology, immunotherapy : CII 2020 Dec;69(12):2477-2499

An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.

Wei J, Wang YH, Lee CY, Truillet C, Oh DY, Xu Y, Ruggero D, Flavell RR, VanBrocklin HF, Seo Y, Craik CS, Fong L, Wang CI, Evans MJ
Molecular imaging and biology 2020 Dec;22(6):1553-1561

Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma.

Zhao G, Chen W, He J, Cui C, Zhao L, Zhao Y, Sun C, Nie D, Jin F, Kong L
World neurosurgery 2020 Dec;144:e660-e673

PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.

Tuminello S, Sikavi D, Veluswamy R, Gamarra C, Lieberman-Cribbin W, Flores R, Taioli E
Translational lung cancer research 2020 Aug;9(4):1343-1360

Down Regulation of c-FLIP_L Enhance PD-1 Blockade Efficacy in B16 Melanoma.

Wang Y, Li JJ, Ba HJ, Wang KF, Wen XZ, Li DD, Zhu XF, Zhang XS
Frontiers in oncology 2019;9:857

Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma.

Guo C, Zhao H, Wang Y, Bai S, Yang Z, Wei F, Ren X
Frontiers in oncology 2019;9:439

PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival.

Liu S, Qin T, Jia Y, Li K
Frontiers in oncology 2019;9:189

Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell Resistance to Doxorubicin.

Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, Gu W, Kui F, Li J, Geng S, Du G
Frontiers in pharmacology 2019;10:1658

EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells.

Zhao Y, Wang XX, Wu W, Long H, Huang J, Wang Z, Li T, Tang S, Zhu B, Chen D
Biochemical and biophysical research communications 2019 Sep 17;517(2):201-209

Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway.

Chen M, Gilbert N, Liu H
Reproductive biology and endocrinology : RB&E 2019 Oct 27;17(1):86

FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.

Li P, Huang T, Zou Q, Liu D, Wang Y, Tan X, Wei Y, Qiu H
Journal of immunology (Baltimore, Md. : 1950) 2019 May 15;202(10):3065-3075

Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.

Xu Y, Cui G, Jiang Z, Li N, Zhang X
Oncology letters 2019 Mar;17(3):2960-2968

Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.

Wang T, Chen S, Wang X, Huang Y, Qiu J, Fei Y, Chaulagain A, Chen Y, Wang Y, Lin L, Yan B, Wang Y, Wang W, Zhao W, Zhong Z
Antiviral research 2019 Jun;166:1-10

PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.

Amoils M, Kim J, Lee C, Sunwoo JB, Colevas AD, Aasi SZ, Hollmig ST, Ma Y, Divi V
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2019 Jan;160(1):93-99

CDK5 Regulates PD-L1 Expression and Cell Maturation in Dendritic Cells of CRSwNP.

Liu CC, Zhang HL, Zhi LL, Jin P, Zhao L, Li T, Zhou XM, Sun DS, Cheng GH, Xin Q, Shi L, Xia M
Inflammation 2019 Feb;42(1):135-144

MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.

Xiong W, Deng H, Huang C, Zen C, Jian C, Ye K, Zhong Z, Zhao X, Zhu L
Biochimica et biophysica acta. Molecular basis of disease 2019 Feb 1;1865(2):454-463

Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.

Jin J, Si J, Liu Y, Wang H, Ni R, Wang J
Respiratory research 2018 Oct 5;19(1):197

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.

Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, Chen CT, Liao HW, Kuo CW, Khoo KH, Hsu JL, Li CW, Lim SO, Chang SS, Chen YC, Ren GX, Hung MC
Nature communications 2018 May 15;9(1):1908

Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.

Guo J, Qu H, Shan T, Chen Y, Chen Y, Xia J
Molecules and cells 2018 Jul 31;41(7):653-664

MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice.

Zhen J, Chen W
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018 Jan;97:1479-1485

A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.

Cannon JGD, Russell JS, Kim J, Chang ALS
JAAD case reports 2018 Apr;4(3):248-250

Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma.

Dai X, Pi G, Yang SL, Chen GG, Liu LP, Dong HH
Translational oncology 2018 Apr;11(2):559-566

Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.

Jiao Q, Liu C, Li W, Li W, Fang F, Qian Q, Zhang X
Clinical and experimental immunology 2017 Jun;188(3):420-429

Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma.

Dai X, Xue J, Hu J, Yang SL, Chen GG, Lai PBS, Yu C, Zeng C, Fang X, Pan X, Zhang T
Translational oncology 2017 Aug;10(4):511-517

Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.

Chang J, Zhu GA, Cheung C, Li S, Kim J, Chang AL
JAMA dermatology 2017 Apr 1;153(4):285-290

Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.

Song Z, Yu X, Zhang Y
Lung cancer (Amsterdam, Netherlands) 2016 Sep;99:166-71

Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report.

Pi G, He H, Bi J, Li Y, Li Y, Zhang Y, Wang M, Han G, Lin C
Medicine 2016 Oct;95(40):e5077

Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.

Takada K, Okamoto T, Shoji F, Shimokawa M, Akamine T, Takamori S, Katsura M, Suzuki Y, Fujishita T, Toyokawa G, Morodomi Y, Okano S, Oda Y, Maehara Y
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Nov;11(11):1879-1890

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.

Song Z, Yu X, Cheng G, Zhang Y
Journal of translational medicine 2016 Jun 24;14(1):188

PD-L1 Expression in Lung Cancer.

Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 Jul;11(7):964-75

PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.

Chang YL, Yang CY, Lin MW, Wu CT, Yang PC
Lung cancer (Amsterdam, Netherlands) 2015 Jun;88(3):254-9

No comments: Submit comment

No validations: Submit validation data